Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Active not recruiting 2Terminated 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Lymphoid 1CNS 1

Conditions

Plasmablastic Lymphoma 1Lymphomatoid Granulomatosis 1Lymphoma, Primary Effusion 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Lung Neoplasms 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1Burkitt Lymphoma 1

Interventions

pembrolizumab 1282Specimen Handling 927Carboplatin 836Magnetic Resonance Spectroscopy 834Cyclophosphamide 807Cisplatin 735Nivolumab 680Paclitaxel 635Radiotherapy 617Gemcitabine 580Biopsy 559Bevacizumab 485Dexamethasone 444fludarabine 410Docetaxel 385venetoclax 372Oxaliplatin 367Capecitabine 361Fluorouracil 357atezolizumab 350durvalumab 340Rituximab 335Drug Therapy 333Radiosurgery 321Doxorubicin 319Blood Specimen Collection 317Standard of Care 311Pemetrexed 307Ipilimumab 303Radiation 287

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
varlilumab × 1 year × Clear all
NCT03688178 2026-05-22

DERIVe

Duke University

Phase 2 Active not recruiting
43 enrolled
CNS

Glioblastoma

NCT03038672 2026-05-12

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

National Cancer Institute (NCI)

Phase 2 Active not recruiting
54 enrolled 12 charts
Lymphoid

Plasmablastic Lymphoma, Burkitt Lymphoma, Lymphomatoid Granulomatosis, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Primary Effusion

NCT04081688 2026-02-05

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

Rutgers, The State University of New Jersey

Phase 1 Terminated
16 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡